Mergers & Acquisitions
May 30, 2014
$50 billion may still not be enough for Allergan shareholders
Just a day after issuing a scathing presentation to shareholders denouncing its would-be acquirer's business model, Allergan Inc. received a sweetened $50 billion buyout offer from Valeant Pharmaceuticals International Inc. on Wednesday.
Daily Journal Staff Writer
Just a day after issuing a scathing presentation to shareholders denouncing its would-be acquirer's business model, Allergan Inc. received a sweetened $50 billion buyout offer from Valeant Pharmaceuticals International Inc. on Wednesday.
Valeant bolstered the cash component of its unsolicited bid for the Irvine-based drug maker to $58.30 per share, a bump of $10 per share from its previous of...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In